Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The global landscape of cancer cell therapy.
Tang J, Hubbard-Lucey VM, Pearce L, O'Donnell-Tormey J, Shalabi A. Tang J, et al. Nat Rev Drug Discov. 2018 Jul;17(7):465-466. doi: 10.1038/nrd.2018.74. Epub 2018 May 25. Nat Rev Drug Discov. 2018. PMID: 29795477 No abstract available.
Trends in the global immuno-oncology landscape.
Tang J, Pearce L, O'Donnell-Tormey J, Hubbard-Lucey VM. Tang J, et al. Nat Rev Drug Discov. 2018 Nov;17(11):783-784. doi: 10.1038/nrd.2018.167. Epub 2018 Oct 19. Nat Rev Drug Discov. 2018. PMID: 30337722 No abstract available.
The global pipeline of cell therapies for cancer.
Xin Yu J, Hubbard-Lucey VM, Tang J. Xin Yu J, et al. Nat Rev Drug Discov. 2019 Oct;18(11):821-822. doi: 10.1038/d41573-019-00090-z. Nat Rev Drug Discov. 2019. PMID: 31673124 No abstract available.
Trends in the global immuno-oncology landscape.
Tang J, Pearce L, O'Donnell-Tormey J, Hubbard-Lucey VM. Tang J, et al. Nat Rev Drug Discov. 2018 Dec;17(12):922. doi: 10.1038/nrd.2018.202. Epub 2018 Oct 26. Nat Rev Drug Discov. 2018. PMID: 30361553
Immuno-oncology drug development goes global.
Xin Yu J, Hubbard-Lucey VM, Tang J. Xin Yu J, et al. Among authors: hubbard lucey vm. Nat Rev Drug Discov. 2019 Nov;18(12):899-900. doi: 10.1038/d41573-019-00167-9. Nat Rev Drug Discov. 2019. PMID: 31780841 No abstract available.
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.
Padrón LJ, Maurer DM, O'Hara MH, O'Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Yu JX, Pfeiffer SM, Spasic M, Xu J, Gherardini PF, Karakunnel J, Mick R, Alanio C, Byrne KT, Hollmann TJ, Moore JS, Jones DD, Tognetti M, Chen RO, Yang X, Salvador L, Wherry EJ, Dugan U, O'Donnell-Tormey J, Butterfield LH, Hubbard-Lucey VM, Ibrahim R, Fairchild J, Bucktrout S, LaVallee TM, Vonderheide RH. Padrón LJ, et al. Among authors: hubbard lucey vm. Nat Med. 2022 Jun;28(6):1167-1177. doi: 10.1038/s41591-022-01829-9. Epub 2022 Jun 3. Nat Med. 2022. PMID: 35662283 Free PMC article. Clinical Trial.
A Blueprint to Advance Colorectal Cancer Immunotherapies.
Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA Jr, Fridman WH, Goldberg RM, Hamilton SR, Housseau F, Jaffee EM, Kang SP, Krishnamurthi SS, Lieu CH, Messersmith W, Sears CL, Segal NH, Yang A, Moss RA, Cha E, O'Donnell-Tormey J, Roach N, Davis AQ, McAbee K, Worrall S, Benson AB. Le DT, et al. Cancer Immunol Res. 2017 Nov;5(11):942-949. doi: 10.1158/2326-6066.CIR-17-0375. Epub 2017 Oct 16. Cancer Immunol Res. 2017. PMID: 29038296
25 results